Copyright
©The Author(s) 2025.
World J Stem Cells. Mar 26, 2025; 17(3): 102067
Published online Mar 26, 2025. doi: 10.4252/wjsc.v17.i3.102067
Published online Mar 26, 2025. doi: 10.4252/wjsc.v17.i3.102067
Figure 3 Effect of cryopreserved mesenchymal stem cell therapy on left ventricular ejection fraction sub-grouped according to cell source: Umbilical cord-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells.
A: Change from the baseline to six months of follow-up; B: Change from the baseline to twelve months of follow-up; hUC-MSC: Human umbilical cord-derived mesenchymal stem cell; BM-MSC: Bone marrow-derived mesenchymal stem cell.
- Citation: Safwan M, Bourgleh MS, Haider KH. Clinical experience with cryopreserved mesenchymal stem cells for cardiovascular applications: A systematic review. World J Stem Cells 2025; 17(3): 102067
- URL: https://www.wjgnet.com/1948-0210/full/v17/i3/102067.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v17.i3.102067